Briakinumab: Phase III data

The double-blind Phase III M10-315 trial in 350 patients showed that briakinumab met the co-primary endpoint of a significantly greater proportion of patients achieving a PASI 75 response at week 12 vs. both Enbrel etanercept and placebo (80.6% vs. 39.6% and 6.9%, respectively; p<0.001 for both). Briakinumab also met the co-primary endpoint of a significantly greater proportion of patients with a PGA score of 0 or 1 at week 12 vs. both Enbrel and placebo (72.7% vs. 29.5% and 4.2%, respectively; p<0.001 for both). ...